(6R)-6-[(8S,9S,10R,13R,14S,17R)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylheptane-3,3-diol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (6R)-6-[(8S,9S,10R,13R,14S,17R)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylheptane-3,3-diol
• 化学式: C₂₇H₄₆O₂
• 分子量: 402.7
• InChiKey: OLHPOGWHUCHIQT-NFSSVYEPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.8
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Th-17 differentiation markers for rosacea and uses thereof
  申请人：Steinhoff Martin

  公开号：US10370714B2

  公开（公告）日：2019-08-06

  A method is described that uses ROR gamma t, or ROR alpha to diagnose rosacea and/or to screen inhibitors of Th17 differentiation, notably in inhibiting ROR gamma t or ROR alpha. Also described is a method of using these screened inhibitors in rosacea treatment.

  描述了一种利用 ROR gamma t 或 ROR alpha 诊断酒渣鼻和/或筛选 Th17 分化抑制剂的方法，特别是抑制 ROR gamma t 或 ROR alpha 的方法。还描述了将这些筛选出的抑制剂用于酒糟鼻治疗的方法。
• Th17 differentiation markers for acne and uses thereof
  申请人：GALDERMA RESEARCH & DEVELOPMENT

  公开号：US10760129B2

  公开（公告）日：2020-09-01

  A method is described for using ROR gamma t or ROR alpha to diagnose acne and/or to screen inhibitors of Th17 differentiation. Specifically described, are methods of inhibiting ROR gamma t or ROR alpha and use of the screened inhibitors in acne treatment.

  描述了一种使用 ROR gamma t 或 ROR alpha 诊断痤疮和/或筛选 Th17 分化抑制剂的方法。具体描述了抑制 ROR gamma t 或 ROR alpha 的方法，以及将筛选出的抑制剂用于痤疮治疗的方法。
• NEW TH17 DIFFERENTIATION MARKERS FOR ACNE AND USES THEREOF
  申请人：Galderma Research & Development

  公开号：EP2723889B1

  公开（公告）日：2019-11-06
• EP2723893B1
  申请人：——

  公开号：EP2723893B1

  公开（公告）日：2018-11-21
• TH-17 DIFFERENTIATION MARKERS FOR ROSACEA AND USES THEREOF
  申请人：Steinhoff Martin

  公开号：US20140221231A1

  公开（公告）日：2014-08-07

  A method is described that uses ROR gamma t, or ROR alpha to diagnose rosacea and/or to screen inhibitors of Th17 differentiation, notably in inhibiting ROR gamma t or ROR alpha. Also described is a method of using these screened inhibitors in rosacea treatment.